|
**Overview**: **OncoPro Cancertrack Minimal Residual Disease Follow-Up Panel****Introduction**: The OncoPro Cancertrack Minimal Residual Disease Follow-Up Panel Test is a diagnostic tool designed to monitor circulating tumor DNA and tumor-specific mutations in plasma samples, facilitating the assessment of cancer recurrence. Associated with various cancers post-treatment, this oncologic condition presents with fatigue, weight loss, and severe complications like relapse if undetected, particularly in individuals with prior cancer history. Per the 2023 American Society of Clinical Oncology guidelines, the test employs molecular pathology with PCR technology, delivering detailed genetic identification over 5-7 days with high sensitivity and specificity, making it a valuable tool for follow-up monitoring in molecular pathology settings. This diagnostic falls under cancer screening and targets individuals with systemic symptoms post-treatment, addressing the challenge of accurate residual disease classification to guide adjuvant therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its plasma-based approach ensures non-invasive detection.**Other Names**: Cancertrack MRD Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by various molecular labs, this test advanced cancer surveillance by standardizing MRD detection.**Purpose**: The test monitors circulating tumor DNA and tumor-specific mutations to guide cancer recurrence assessment, assess oncologic status, and inform treatment and prevention strategies.**Test Parameters**: Presence of circulating tumor DNA and tumor-specific mutations, detected with high specificity to indicate residual cancerous activity, typically observable in plasma at altered genetic patterns during active disease, with DNA levels and mutation status assessed to determine severity and distribution, providing a comprehensive profile of tumor damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected genetic components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, weight loss, or recent cancer treatment.**Specimen**: Plasma 2-4 mL, collected using EDTA tubes, transported within 8 hours to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling in a cool environment to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade DNA, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on fatigue, weight loss, prior cancer, or family history of oncologic disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated recurrence including metastasis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves plasma processing, DNA extraction, PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 5-7 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 8 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible cancer recurrence, necessitating further investigation like imaging or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.**Specialist Consultation**: Oncologists should be consulted for case management, treatment planning, and coordination with cancer programs.**Additional Supporting Tests**: PET scan, biopsy review, or CEA testing for confirmation.**Test Limitations**: The test may produce false negatives in low tumor burden or false positives in contamination, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ASCO Guidelines 2023, Journal of Molecular Diagnostics 2024, Molecular Pathology 2025. |
